Merck's team arrived at ASCO with some solid positive data backing their melanoma program for lambrolizumab (MK-3475). The pharma giant is readying a pair of late-stage clinical trials for melanoma and non-small cell lung cancer as they set their sights on completing a speedy set of applications for regulators.
Interim results from Amgen's Phase III trial demonstrated the ability of talimogene laherparepvec, the oncolytic virus known as T-Vec, to shrink tumors while delivering some early signs of improved survival rates for melanoma patients.
Bristol-Myers Squibb arrived at ASCO with one of the most closely watched experimental immunotherapy drugs in the pipeline. And racing against some major league rivals, the biopharma company will leave with its frontrunner reputation for nivolumab intact.
In an important win for GlaxoSmithKline's R&D division, the FDA today announced that it has approved a pair of genetically targeted melanoma drugs, dabrafenib and trametinib, from the company, along with a diagnostic test that can be used to identify the patients most likely to respond to the treatments.
Amgen touted top-line results from a Phase III trial of an anti-cancer virus as a treatment for a deadly form of skin cancer, showing that talimogene laherparepvec met the primary goal for shrinking tumors in patients with late stages of the disease.
Navidea Biopharmaceuticals prevailed on the regulatory front with an FDA approval for the company's ($NAVB) imaging drug for patients with breast cancer and melanoma.
GlaxoSmithKline has stepped up its late-stage program to advance a combo of targeted cancer drugs against deadly skin cancer, with a new study to see whether its experimental BRAF and MEK inhibitors can keep melanoma from coming back after surgeries.
Genentech has joined a race to prove that two kinds of targeted cancer drugs are better than one of them. It's jumped into a late-stage trial of a two-drug combo therapy against deadly skin cancer amid growing competition for such treatments in the pharma industry.
Researchers say the data reflect a positive trend for overall survival.
Will Abraxane join the new gang of melanoma fighters?